Risk to Business Progress from the Spread of COVID-19
First written in FY2020-Q2. 4 of 13 entries say "Restated". Latest entry: FY2024-Q2.
Medinet moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
51 other companies' latest entry also says "Mitigated".
- FY2024-Q2MitigatedAnnual report
「During the cumulative second quarter (from 1 October 2023 to 31 March 2024), economic activity continued to normalize and the employment and income environment improved, with the economy showing a moderate recovery trend.」
The company indicated that economic activity had continued to normalize and that the previously observed improvement in the business-operation risk from the spread of COVID-19 had continued. - FY2024-Q1MitigatedAnnual report
「During the cumulative first quarter (from 1 October 2023 to 31 December 2023), COVID-19 had subsided and economic activity was moving further toward normalization, while the economy was recovering moderately.」
The company indicated that COVID-19 had subsided and economic activity had moved further toward normalization, and the business-operation risk from the spread of the infection had eased further. - FY2023-Q3MitigatedAnnual report
「COVID-19 restrictions were eased from the equivalent of Category 2 to Category 5, and economic activity is moving toward normalization as the flow of people increases.」
The company described the easing of the COVID-19 classification, increased movement of people, and progress toward normalization of economic activity, indicating some improvement in the previously identified business-operation risk. At the same time, it stated that uncertainty about the outlook remained. - FY2023-Q2MitigatedAnnual report
「The effects of COVID-19 are gradually easing, and economic activity is moving toward normalization.」
The company indicated that the business environment is improving, with the effects of COVID-19 gradually easing and economic activity moving toward normalization. - FY2023-Q1RestatedAnnual report
「The business environment surrounding the company remains difficult, and conditions continue to be unpredictable, including with respect to the effects of COVID-19 variants.」
While economic activity is normalizing as restrictions on movement are eased, uncertainty about the business impact of COVID-19 variants and other factors persists. - FY2022-Q3RestatedAnnual report
「However, the effects of the prolonged COVID-19 pandemic continue to be felt at the medical institutions that are the company's business partners, and the company's business remains in a difficult situation.」
The prolonged COVID-19 pandemic and its impact on business-partner medical institutions continued, and the company continued to describe the business environment as difficult. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter (from 1 October 2021 to 31 March 2022), efforts were made to balance measures against COVID-19 with economic activity, but uncertainty about the outlook persisted as infections with more transmissible variants and other strains spread again.」
While efforts to balance measures against COVID-19 with economic activity advanced, the company continued to explain that the outlook remained uncertain because of the renewed spread of highly transmissible variants and other strains. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter (from 1 October 2021 to 31 December 2021), efforts to balance measures against COVID-19 with economic activity advanced, but uncertainty about the outlook persisted, including concerns about another spread of COVID-19 caused by new variants.」
The company continued to identify the effects of COVID-19 and concerns about another spread caused by new variants as sources of uncertainty in the business environment. - FY2021-Q3WorsenedAnnual report
「During the cumulative third quarter (from 1 October 2020 to 30 June 2021), there was still no clear prospect of containing the spread of COVID-19, and severe conditions continued, with restrictions on corporate and economic activity still unavoidable.」
With no clear prospect of containing COVID-19, the effects of restrictions on business activities and sluggish patient numbers have persisted. - FY2021-Q2WorsenedAnnual report
「There is still no clear prospect of containing the spread of COVID-19, and severe conditions continue, with restrictions on corporate and economic activity still unavoidable.」
The prolonged spread of COVID-19 continued to affect the business, with sluggish inbound patient numbers, a 45.7% decrease in net sales, and the cell-processing business segment falling into the red. - FY2021-Q1WorsenedAnnual report
「There is still no clear prospect of containing the spread of COVID-19, and severe conditions continue, with restrictions on corporate and economic activity still unavoidable.」
The spread of COVID-19 was not contained and its effects persisted, with the impact on the business expanding to include sluggish inbound patient numbers and a 52.7% decrease in net sales. - FY2020-Q3MaterialisedAnnual report
「Revenue was ¥637 million, down 15.6% year on year, mainly due to a decline in cell processing revenue resulting from a decrease in the number of inbound patients at affiliated medical institutions following the spread of COVID-19 and other factors.」
The impact of COVID-19 materialized as a decline in inbound patients and a 15.6% decrease in net sales. - FY2020-Q2First statedAnnual report
「If the spread of COVID-19 makes it difficult to conduct business smoothly, for example through lower sales, reduced financing due to a depressed share price, or the suspension or postponement of contract manufacturing of processed cells if employees become infected, this could affect the Company’s performance and business development.」
The Company identifies the spread of COVID-19 as a new business risk, citing possible declines in sales and financing and suspension or postponement of contract manufacturing.